Insider Selling: uniQure (NASDAQ:QURE) Director Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director David Meek sold 1,993 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the sale, the director directly owned 39,747 shares in the company, valued at $1,075,553.82. This trade represents a 4.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

uniQure Price Performance

Shares of QURE traded up $0.75 during mid-day trading on Friday, hitting $27.57. 835,627 shares of the stock were exchanged, compared to its average volume of 2,601,234. The company has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The firm has a 50-day moving average of $22.31 and a two-hundred day moving average of $21.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, equities analysts predict that uniQure N.V. will post -3.64 earnings per share for the current year.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. CIBC Private Wealth Group LLC purchased a new stake in uniQure in the third quarter worth $50,000. Torren Management LLC purchased a new stake in uniQure in the fourth quarter worth $28,000. FNY Investment Advisers LLC increased its stake in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. Finally, IFP Advisors Inc purchased a new stake in uniQure in the fourth quarter worth $48,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wolfe Research assumed coverage on uniQure in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. The Goldman Sachs Group increased their price target on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, April 20th. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $11.00 to $35.00 in a report on Monday, March 9th. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and increased their price target for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.